Medical Condition News

RSS

Combat in Iraq associated with post-deployment PTSD, depression in 8.5 to 14% of soldiers

Between 8.5 percent and 14 percent of soldiers returning from Iraq report serious functional impairment due to either posttraumatic stress disorder or depression, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Jun 2010

Children and teens with moderate to severe OSA have lower academic grades: Research

The average academic grades of children and teens with moderate to severe obstructive sleep apnea are worse than the grades of students who have no sleep-disordered breathing, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Research findings open door to development of new therapies for lymphomas, leukemias

Scripps Research Institute scientists have discovered a new way to target and destroy a type of cancerous cell. The findings may lead to the development of new therapies to treat lymphomas, leukemias, and related cancers.

8 Jun 2010

Nighttime noise disturbs sleep, impairs neurobehavioral performance in the morning: Research

Nighttime noise from nearby road traffic, passing trains and overhead planes disturbs sleep and impairs morning performance, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

Myriad Pharmaceuticals, Inc. today announced the presentation of clinical data from two separate Phase 2a combination drug studies of AzixaTM (MPC-6827, verubulin) at the American Society of Clinical Oncology 2010 Annual Meeting in Chicago, IL. Results from studies in both recurrent glioblastoma multiforme and stage 4 metastatic melanoma demonstrated that Azixa, in combination with standard treatments, resulted in durable responses with no added toxicity compared with chemotherapy alone.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx, Inc. today presented additional results from the Ostarine™ Phase IIb study demonstrating an improvement in quality of life (fatigue and anorexia) in cancer patients with muscle wasting (cancer cachexia) who demonstrated improvement in functional performance as measured by stair climb. Ostarine (GTx-024) is GTx's lead selective androgen receptor modulator (SARM) which the company is developing for the treatment of cancer cachexia.

8 Jun 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

In a surprising discovery that someday may lead to new treatments for many inflammatory diseases, University of Utah scientists found that a hormone involved in iron metabolism can save mice from deadly acute inflammation.

8 Jun 2010

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

A rare but fatal disease of blood vessels in the lung may be caused in part by aberrant silencing of genes rather than genetic mutation, new research reports. Pulmonary arterial hypertension, a syndrome characterized by gradual blockage of blood vessels in the lungs, has been linked to genetic causes in a small percentage of patients. But University of Chicago researchers have now found that a form of epigenetics - the modification of gene expression - causes the disease in an animal model and could contribute to the disease in humans.

8 Jun 2010

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors.

8 Jun 2010

Quintiles announces comprehensive suite of PI3K biomarker assays

Quintiles today announced a comprehensive suite of biomarker assays to help biopharmaceutical companies investigate the phosphoinositide 3-kinases (PI3K) cancer survival pathway, the focus of numerous anti-cancer therapies under development. Understanding the PI3K pathway is essential in developing new medicines to inhibit or block this pathway, thereby cutting off a metabolic function needed for certain cancers to survive.

8 Jun 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta Pharmaceuticals Corp. announced that clinical results for two Phase 1 trials of STA-9090 in solid tumors, as well as 12 month updated survival results from the SYMMETRY trial of elesclomol in metastatic melanoma, were presented at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO).

8 Jun 2010

FSPs designed to improve residential stability, mental health outcomes for homeless persons with mental illness

Full-Service Partnerships are designed to do 'whatever it takes' to improve residential stability and mental health outcomes for homeless persons with serious mental illness. They are the cornerstone of California's Mental Health Services Act - one of the largest mental health policy experiments in recent history.

8 Jun 2010

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

Threshold Pharmaceuticals, Inc. today announced results from Phase 1/2 clinical trials in various solid tumors related to its hypoxia-activated prodrug, TH-302. The results were presented during the American Society for Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL.

8 Jun 2010

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

A community-based health promotion program delivered by over 500 peer volunteers significantly reduces heart disease and stroke in seniors, Canadian Stroke Network researcher Dr. Janusz Kaczorowski told the Canadian Stroke Congress today.

8 Jun 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg.

8 Jun 2010

Long sleep duration associated with elevated prevalence of metabolic syndrome in older adults: Study

Long sleep duration is associated with an elevated prevalence of metabolic syndrome in older adults, according to a research abstract that will be presented Tuesday, June 8, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

8 Jun 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from an ongoing Phase 1 study of its investigational pan-BCR-ABL inhibitor, AP24534, in patients with resistant and refractory chronic myeloid leukemia (CML). The data confirm strong clinical evidence of hematologic, cytogenetic and molecular anti-leukemia activity of AP24534, a multi-targeted kinase inhibitor, in heavily pretreated patients with CML, including those with the T315I mutation of the target protein, BCR-ABL.

8 Jun 2010

Greatbatch celebrates 50th anniversary of first successful US human cardiac pacemaker implantation

Greatbatch, Inc. is proud to join the medical community in celebrating the 50th anniversary of the first successful implantation of the human cardiac pacemaker in the United States. The pacemaker was designed, developed and implanted by Wilson Greatbatch in conjunction with William M. Chardack, M.D. and Andrew A. Gage, M.D.

8 Jun 2010

Medical Condition News

Combat in Iraq associated with post-deployment PTSD, depression in 8.5 to 14% of soldiers

Children and teens with moderate to severe OSA have lower academic grades: Research

Research findings open door to development of new therapies for lymphomas, leukemias

Nighttime noise disturbs sleep, impairs neurobehavioral performance in the morning: Research

Clinical data from two separate Phase 2a combination drug studies of Azixa presented at ASCO 2010

La Jolla Institute scientist finds protein key to insulin secretion

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Hormone involved in iron metabolism can save mice from deadly acute inflammation: Scientists

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Interim results from Micromet's MT110 BiTE antibody Phase 1 trial presented at ASCO

Quintiles announces comprehensive suite of PI3K biomarker assays

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

FSPs designed to improve residential stability, mental health outcomes for homeless persons with mental illness

Threshold Pharmaceuticals presents results of TH-302 Phase 1/2 trials in solid tumors at ASCO

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Community-based health promotion program reduces heart disease, stroke in seniors: Researcher

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

Long sleep duration associated with elevated prevalence of metabolic syndrome in older adults: Study

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Greatbatch celebrates 50th anniversary of first successful US human cardiac pacemaker implantation

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Latest News